Triple-negative breast cancer (TNBC), accounting for about 15–20% of total, is a subtype characterized by lack of estrogen receptor (ER) and progesterone receptor (PR) expression and lack of ERBB2 (also known as HER2) amplification (Foulkes et al., 2010). Here, ERBB2 is linked to triple-negative breast carcinoma.